Q3 2020 Amneal Pharmaceuticals Inc Earnings Call
[music].
All of that anybody come back I thought was good morning, and welcome to the Aneel third quarter Twentytwenty earnings call. All participants will be in listen only mode. If you need assistance. Please signally conference specialist by pressing Star then zero on your telephone keypad.
After todays presentation, there will be an opportunity to ask questions.
Few questions you May Cross Star then one on your telephone keypad to withdraw your question. Please press Star then too.
Please note this event is being recorded.
I would now like to turn the conference over to be on deals Chief Financial Officer Tussaud's kind of targets. Please go ahead.
Thank you Andrew Good morning, and thank you for joining us for Emil to third quarter 2020 earnings call.
Earlier. This morning, we issued a press release reporting our quarterly results the press release as well as the slides that will be presented on this call are available on our website at www Dot Amneal dotcom.
We're conducting a live webcast of this call a replay of which will be also available on our website. After its conclusion.
Please note that today's call is copyrighted material of Emil and cannot be recorded broadcast without the company's expressed written consent.
I would like to remind you that statements made during this call, stating management's outlook or predictions for the future future forward looking statements.
These statements are based solely on information that is now available to us.
Encourage you to review the sections entitled cautionary statements on forward looking statements No press release and presentation, which applies to this call our.
Our future performance may differ due to numerous factors mannion, we totally within our most recent annual report on form 10-K, and our revised and updated on a quarterly reports on form 10-Q, including reports on form 8-K, which you can also find on our website or on the Fccs website the FCC.
Dugout.
We'll also discuss certain non-GAAP measures you will find important information on our use of these measures reconciliation to U.S GAAP in our earnings release include.
Included in the appendix of todays presentation, you will find us GAAP financial statements that correspond to some of our non us GAAP measures we referenced throughout the presentation.
On the call. This morning are Shira August continued Patel of co Ceos and before year uncertainty Scott, our chief commercial officer support our generics and specialty segments as well as statements I know general counsel and corporate Secretary.
I will now turn the call over to Ron.
Good morning, and thank you for joining us in the review of revenues current quarters those.
We are pleased with the strong performance this quarter versus prior year with net revenue of $519 million up 37% or just to the bank or $114 million up 16% and adjusted EPS of 16 cents of substance substantially.
Versus four cents per.
Our strong and consistent financial performance over the course of 2020 reflects the successful execution of our.
Our revenue 2.0 strategy.
This could not have been possible without their resiliency and excellent work of our global team we.
We know their dedication and commitment to providing affordable and innovative medicines to patients is an integral part of navigating the COVID-19 dynamic this year.
We all know how difficult the last few months have been due to covering 90 and unfortunately, we are clearly not out of the woods yet.
From our perspective in Q3, we saw us sequential pickup in demand and lower supply chain disruption compared to the second quarter.
Having said that we continue to be vigilant and actively preparing for the next wave of core Weve 19 to ensure we meet the demands of our customers and avoid any material disruptions over the coming months.
As we discussed in our first quarter 2020 call.
Despite that make raised the issue of domestic preparedness.
And the need to fortify production of critical medicines based in the United States and.
And Neal is the largest us generics company domiciled in the United States, and we believe our operational expertise and excellent quality track record uniquely positions us to be part of an expanded domestic drug manufacturing strategy.
Over the course of last few months, we have spent substantial amount of energy and resources to respond to these bipartisan upward and we look forward to working with legislators from both parties as well as industry to help protect the health and safety of our citizens.
Since we joined as co Ceos last summer, we shared with you our intend to reinvigorate the R&D pipeline.
Successfully launch new products bolster our base business degree.
Diversify our distribution channels and focus on operational excellence to improve profitability.
In Q3, we executed on all these objectives. When we started our generics segment, where net revenue increased 17% compared to Q3 of 2019.
The double digit net revenue growth reflects the successful launch of eight of the 15 complex new products.
We target launching by August 2021, as well as the continued strong performance by during its appropriate.
We are building on our strong presence with a steady flow of new product launches, including Threed printers in hydrochloric tablets for treatment of schizophrenia, and genetics boot trends transdermal system for pain management and showed the generics layer can patch as we mentioned in the past can you.
Beginning to shift our mix of products to more complex or differentiated products is a strategic priority of ours. This is reflected by the substantial increase in our R&D pipeline focused on and no non oral solid products.
In addition to the new product growth.
We were pleased by this trend in our base business.
Growth reflects the relevancy of our goal to grow our commercial portfolio and customer focus by our commercial and supply chain organizations.
Finally, we are constantly looking for ways to leverage originate product portfolio and manufacturing capability in new channels such as over the counter.
An example of such initiatives is the recent launch of the store brand equivalent of Walters, uncertainties, HL, which we introduced in partnership with Pls Tom.
Topline growth as well as keeping a close eye on operating efficiencies led to a substantial increase in generics and district gross margin to 37.4% compared to 29.8% in Q3 of 2019.
As co Ceos, along with our broader team we are acutely focused on operational excellence continuing to find ways to improve efficiency and optimize our expense base is a key component of our revenue 2.0 strategy. We have a robust list of companywide activities from gross to net deductions to break.
Shifting into manufacturing last year expenses, which will help drive generics anticipate gross margin above 40% over the course of time.
Let me now turn over to our specialty segment, where our business was stable compared with the prior year we.
We feel good about this performance considering the fact, we came off a very strong second quarter and the headwind on COVID-19 is having on the physician office visits and new patient starts both right reengineering growing continued to show strong growth with sales up approximately 12% in 2009.
5%, respectively, and combining prescriptions volume up 6%.
Moving onto healthcare, which continues to generate strong topline growth revenues increased to 89.5 billion from 64 million in the prior quarter banking team has done a nice job growing the topline business. Despite a slowdown in new product introductions from third party suppliers.
Look over 19, and usually such new products carry high much higher margins. We continue to be excited about the long term opportunities in the growing Goldman segment.
With that let me turn the call over to chip for now.
Good morning, everyone. Thank you Gerard let me first start with the recorded 19 response and I Echo My brother sentiment.
Truly proud of our team members have responded and are working with our customers and suppliers to mitigate interruptions last quarter, we discussed that approximately $20 million of customers orders were not field due to coal Weve 19 disruptions in the third quarter on full field orders.
<unk> declined to approximately $10 million and I'm pleased to report that overall, our manufacturing facilities are operating close to the COVID-19 levels. We are building of inventory on hand, and strengthening our global supply chain.
As Doug mentioned since we joined last August we have led a number of strategic initiatives to improve performance in a sustainable way, including rebuilding the R&D pipeline as well as operational excellence to improve efficiency across our supply chain, let me spend a few minutes highlighting or generic.
Segment and R&D pipeline.
Action, we take is aligned to our quality parts mindset and the continued its strong quality track record as demonstrated by successfully inspections in 2020 and all prior years.
Our generic business continues to improve with strong sales and increasing margins. Our results reflect strong volume gains and increased manufacturing port alluding, which enables our commercial team to increase its market share to 23% compared to 15% in the second quarter. In addition.
We are on track to be worth 15 highly complex generic products by next August and plan to price close to 30 and B is this year up from our prior expectations of 20 to 25.
Our portfolio transition to complex generics continues and over 60% of this 30, indeed, our non oral solid dose.
Also our current pipeline of over 100 products is about 80% non oral solids and includes many complex products to our focused R&D efforts, which are made possible by our in house development and manufacturing capabilities will be constantly refreshing NXP.
Finding other generics pipeline for many years to come our way.
In particular, we are very focused on generating meaningful growth in our injectable product line over the next 18 to 24 months to better meet the demands of our hospital business Fund.
Turning to our specialty pipeline, we have a number of attractive product candidates that we plan to bring to market over the next few years. We are excited about the potential opportunity as they leverage both our R&D team and our commercial infrastructure, let's start with IBX to three which is our next generation product or.
Treatment bulk markets in Parkinson's disease, which we expect will be a material improvement or write 30 and existing therapies BD.
BD, the degenerative disorders that affect booming producing neurons in the brain that affect the moment. Unfortunately.
But on managing that into these purchase trend ended can you share.
Roughly 1 million Parkinson's patients in the pits and approximately 60000, new patients are diagnosed each year.
60% of PD patients in the US are on some form of levodopa therapy and immediate release KBW par is a first line therapy in PD.
Enlink currently market dry dairy and extended release product that is targeted to more moderate to severe patients when generic immediate free Wifi IBX Q3, as addressing the theme patient population is that ideally with improvement in terms of efficacy and patient convenience.
Based on our phase two clinical results, we expect that our phase three clinical trial will demonstrate IBX to three to have a superior profile in terms of good on time, which is the time in which a patient has symptomatic relief without troublesome dyskinesia.
Such benefit may translate to one to two hour per day improvement in good on time, while decreasing the daily dosing two three times what is the current four to six times per day.
Such outcomes would be a material improvement in quality of life for PD patients and expand the addressable market for our product accordingly.
There are currently two phase three clinical trials ongoing and we expect to see topline data in the second half of next year with commercial launch plan for 2023.
Second near term pipeline opportunity in specialty is K 127, which is a firefight be two program for treatment of mild than your various that we in licensed from Kashi bars Sciences last year embodies the radar to immune disease that causes extreme muscle weakness doublevision droopy eyelids and b.
He called his with speech and swallowing cable.
Okay 127 developed through a proprietary drug delivery technology platform is an improved formulation of fighters pigment, which is the most commonly prescribed what's line therapy four mg.
It's successful gave 127 could offer improved tolerability once daily dosing with the rapid onset and 24 hour symptomatic coverage. This product profile would be a significant improvement over the current generic formulation, which is given three to four times a day.
As a point of reference MD, the rare disease affecting 36000 to 60000 patients in the United States. We see these as an attractive commercial opportunity based on the concentrated prescriber base and synergistic deployment with our neurology field team.
We'll be starting the phase three trial for tier 127, Sue and assuming success successful results of the trial, we plan to file this product will be in Twentytwenty two.
Beyond these exciting candidates, we are actively monitoring opportunities to make specialty a larger part of gaming business in the coming years. This includes external partnerships as well as M&A targeting specific platforms that leverage our expertise and have a reasonable probability of success.
In addition, we expect to increase the share of our internal R&D budget.
Directed to branded product development in a measured way.
At last I would like to acknowledge our suppliers customers and employees for their efforts during the quarter, we pandemic and thank them for their hard work and dedication. During these challenging times I will turn the call over to now two parcels.
141 million.
For 37% compared to Q3 2019.
Our our third acquisition accounted for $19 million grow, which implies a quarterly organic net revenue growth of 40%.
So the business generics performed strongly up 17%, while our specialty segment it was consistent with prior year quarter.
This performance reflects solid execution in a challenging, albeit improving market environment.
Carbonite infrastructure continues to be a headwind across selected products and while the value of patient visits his recovery. It is not back to normal levels and acute suffer utilization is lagging as well.
Tim dimension, we're making very good progress in reducing lost sales due to carbonite is supply chain disruptions and were steadily improving our finished goods inventory position.
Adjusted gross profit of 206 million was up 55 million or 36% compared to Q3, 2019, reflecting strong telerik sales occur and stable performance by specialty.
Adjusted gross margin of 39.7% was inline with our expectations and essentially flat to the 40% in Q3 for the nineties.
Excluding the acquisition adjusted gross margin recurring quarter will have been 45%.
So approximately 500 basis points higher than prior year, driven by the Stendal generics.
Adjusted EBITDA of 140 million was up $43 million or 60% compared to Q3, 2019, reflecting strong generic growth tight expense management and the 6 million contribution by market.
Adjusted diluted EPS of 16 cents well ahead of that four cents. We reported in Q3 2019, mainly driven by the adjusted EBITDA growth lower interest expense offsetting higher after minority interest and taxes.
The improvement in business trends and our financial management efforts have resulted in strong operating cash flow.
By nature operating cash flow fluctuated substantially in any given quarter and in this third quarter, we generated 45 million.
Or 273 million here today.
Our year to date performance is substantially ahead of the 53 million, we generated first nine months of 2019.
A strong financial performance is strengthening our balance sheet and improves our financial flexibility.
As of September Thirtyth, we had 284 million in cash and cash equivalents as well as an additional 498 million available to our ABL facility.
Most importantly, our net debt to EBITDA ratio continued to improve to 5.6 x. versus seven X at the end of 2018.
Let me now turn towards segment.
Well generics, which reported net revenue of 342 million.
51 million increase or 17% from.
Prior year quarter.
For 35 million or 12% sequentially.
I will highlight that this performance reflects three factors first.
The benefit of our strategy delivering strong new product introductions.
Sequentially elegance of crowd paid both of which were last late last year more than offset the declines in global tire oxide and diclofenac gel.
Second the resiliency of our base business due to the effectiveness of our commercial initiatives and the relevancy of our growth portfolio of products.
Third less of a headwind than the prior quarter in terms of COVID-19 related backorders and get lingering negative effects on prescription trends in elective surgeries.
Moving on to adjusted gross margin for the generic segment, which was 37.4% subs.
Substantially higher than the 29.8% in Q3, 2019, and 35.3% in second quarter 20 Twond.
The year over year gain reflects new product launches a number of operational improvements and favorable product mix offsetting pricing pressures.
Let me now turn to our specialty segment and we're pleased with the resiliency of our commercial execution, considering the negative impact of cover 90.
Net revenues of 88 million were in line with Q3 2019 as solid demand growth for right regulatory were offset by declines in our non promoted products.
Similarly, adjusted gross margin for the specialty segment was in line with Q3 at approximately 74%.
Turning over to our care with reported net revenues of 90 million and adjusted gross margin of about 15%.
While top line growth has been ahead of our expectations COVID-19 in channel mix is a temporary headwind to our cost structure built.
Furthermore, the fact, the tanker adds substantial revenue was lower margin creates a mathematical headwind to our overall gross margin percent is.
It's clearly demonstrated in the third quarter, but as I mentioned earlier, our care diluted our company gross margin by approximately 500 basis points.
This adverse mix will moderate or even disappear next year as Dr will be in our base the results.
Considering our performance over the course of the year, we delivered his coded to update our full year 2020 guidance specifically.
The new revenue range is 1.95.
2.0 billion.
Up from our prior guidance of 1.875 to 1.975 billion.
Gross margin, 41% to 42% compared to the 44% to 46%, mostly driven by our care.
EBITDA.
Im sorry, adjusted EBITDA 430 million to 460 million.
Up from 400 450 million.
Adjusted EPS 50.
55 cents to 65 cents up from 45 cents to 60 cents.
Operating cash flow to $170 million to $220 million up from $150 million to $200 million and finally capex of $60 million to $70 million no change to prior guidance let.
Let me now a little bit more color around our guidance first we need to be mindful in the middle of the pandemic and impossible to predict are the potential outcomes.
He said that we have a broad portfolio in our manufacturing operations continue to improve that.
Second we expect patient value gradually move towards more normal levels.
Third while R&D engine extension were somewhat tempered this year due to cover nineties, we're expecting an increase in operating expenses as clinical sites are reopening.
With that I'll turn the call back to Sheila. Thank you for ourselves. We are pleased to have made significant gains this year and executing our amnio in 2.0 strategy. Despite the pressures of the COVID-19 pandemic, we'll all look forward to continuing to drive on operational excellence and reinvigorate our pipeline.
I would like to now turn call over to operator to take your questions. Thank you.
We will now begin the question and answer session to ask a question you May Press Star then one on your telephone keypad.
You are using a speakerphone please pick up your handset before pressing the keys if.
Anytime your question has been addressed and you would like to withdraw your question. Please press Star then too.
Please limit yourselves to one question and one follow up.
At this time, we will pause momentarily to assemble our roster.
The first question comes from David Amsellem of Piper Sandler. Please go ahead.
Hey, Thanks, So just just a couple so first I wanted to get your thoughts on.
Biosimilar business and.
There's a couple of questions. There. One is how are you thinking about that program and that's been biosimilars in the context of increasingly competitive marketplace.
And specifically what do you think pricing will behave like.
As more competition poison.
In these markets do you think you will see erosion that sandy can like what you see for small molecule generics.
And then secondly on Biosimilars can you talk about.
The other opportunities.
And when we could get more visibility on other opportunities that you're working on thanks.
Very good morning.
As we mentioned before our Biosimilars will see key products worldwide with FDA one is to be filed soon.
[music].
We are in the opinion, we consider biosimilars as a more complex generics.
Market will behave as such as more competition comes more people more doctors feel comfortable prescribing biosimilars.
Intake from the Congress was to create competition and reduced pricing that's exactly what's happening so.
So from the beginning we have invested very carefully.
And so far we are only commenting on it three programs not commenting on the additional.
Fortunately these we are working on.
The erosion you mentioned like small molecule no that will not happen small molecule as you know it's ridiculous theologians get to 90, 899% I do not expect that.
Extremely hard manufacturing lots of size loss of investments so more like became between.
Complex high value generics and what you see today Biosimilar somewhere in between that's where my guess, we will end up on Biosimilar pricing.
The next question comes from Gary Nachman of BMO capital markets. Please go ahead.
Hi, guys. Good morning, first a little bit of a follow up to the last question. So what have been the dynamics with new launches that you're seeing how much pricing pressure.
How difficult to negotiate managed care contracts and maybe compare elevating and stock of say with percentage being able to launch more recently and then expectations for complex generics going forward.
And then that path.
Process on that the gross margin guidance.
I guess I was surprised that it came that much slower, but the talk a little bit more about the mix that's driving that I know a lot of it is that care, but is there anything else. They can there. Thank you.
Good morning, Sean your questions on complex generics they tend to be immediate pick up by the customers and conversion to the generics are.
Same as how the small molecules.
Been working for years at CVG and conversion to generic so we don't see any difficulties negotiating with managed care.
The complex generics Biosimilars is it.
Holy War game for Us and we are preparing to launch these products as they get approved so we will we're learning how do we have the specialty group we have the managed care Andrew So we'll be negotiating with various stakeholders Marsalis I'll turn it over to passes for thank you.
Good morning.
Yes, there is nothing going on on the on the gross margin.
Other than the impact of Vidacare. So.
As kind of Peel back the audience. So as you know we think about it in terms of those three segments. So lets dig generics would buy the vast majority of which the majority of our business by so year to date as I mentioned were 38.4% margin.
That's 240 basis points up from the same period last year.
And with nine months under our belt. The overall generic margins for the year will be substantially higher.
35%, where we ended up last year. So we feel great about right. So a big part of our business is increasing revenues increasing profitability.
The second largest part of the business right the specialty so that margins they're only.
Gross margins are relatively flat so it's about 75% 70, 475%, but it's a lot of stability there and met and there was a lot of durability right. So we feel great about this and then be the other piece that you have is out here, which was as you know it was a newly acquired.
Business at the end of January So what would the company gave guidance in February is a newly acquired business that business has over perform from a revenue perspective, just to be clear as over pro forma revenue perspective, right and it just it will have its profitability was not as high just because of coffee and slowed down.
New product introductions from.
From other other.
But it's not not not our products so that creates a bigger than expected headwind right or how it could add care was going to impact our results and this is what were reflecting.
By getting the guidance 41, 42%.
As I mentioned ahead next year after in our base upgraded our base. So well continue down that path from a generic standpoint or launching new products continue to expand our business hopefully carbonite it will be mostly behind us. So.
Our our utilization one in manufacturing plants should be better stability or special that we should see an expanded gross margins sugar and also we are working to transfer many products toward us plans for MKS business, which were like two there.
Topline and especially on the gross.
Got it that's starting to address your question.
Yes, that's great. Thank you very much so thank you.
The next question comes from Gregg Gilbert of Truest Securities. Please go ahead.
Thank you good morning attraction too I was hoping you could share with us your thinking about the strategic importance of AAV care longer term.
Obviously, we've lived with the asset for some time now and Thats tough to said, it's performing well financially so.
Serious about the strategic importance of that asset longer term beyond simply being sort of diversification angle.
And Joe I was hoping you could comment on what's going on with right Terry and in terms of.
Your face to face detailing versus other methods you've learned about over the past several months and what's the outlook for continued growth from that important brand. Thank you.
So good morning, Greg.
Sure. So let me on healthcare, we have two actually three revenues within the business one is going business, which we are mostly excited about.
We have multiple products from us and third parties being the largest us up.
Thomas on generics company, we have more products to offer to our portfolio.
Number of products still going on fighting for the government business over the next five years. So were substantially building your pipeline for doing business.
So that we are very excited another bargains unit dose, which is we launched our first product and.
Have built up the capacity to launch eight more products in next next year.
Our strategic importance the server and third segment is a direct to providers, which is a small segment.
And with lower margins in sometimes is how far into.
To create to build or.
Customer borrowing any partnership because lender in shortage, we're able to supply immediately which is why we take during the quarter in time, so income slightly.
The strategic importance is that we are the only as were directly distributing to lower customers. So which allows margin expansion for overall then.
As well as increases cells with different alternative channels. So we continue to be very excited about it.
Hi, Julie.
Thanks, Thanks, Craig for the question, Yes, I think we're pretty pleased with the performance of our targets for the third quarter. Despite the current headwinds obviously, new patient starts has been the biggest challenge across all pharma.
Especially in the patient population that arent going back to their doctor and the regular visits.
Okay.
Remains strong we had a decent amount of what we felt were new patient starts to see some.
Some segment of growth over the prior year, but we've also seen.
Even a script maybe script growth may not be as high revenue growth, you're seeing a higher number of pills per script.
R&D expense and I think thats indicative of more 90 day sales going out the door, which is which is overall good for resale rate on that brand.
Now in terms of the efficacy of the Salesforce, a large part of the second quarter neighbor sidelines due to lockdown.
We added that as most companies in the industry getting became highly effective in.
Virtual promoting holding virtual lunch and learns to resume.
I think going forward and territories and opened up we maintain a mix or a balance between in person detailing and the ability to hold some of these events that we used to do in person virtually which.
Which is why we seen that.
Seen any cost come down a little bit, but we feel good about retiring got runway through 2025 with our settlement and.
Ready to return to growth in 2021.
Thank you.
The next question comes from Ami Fadia of Leerink. Please go ahead.
Hi, good morning, Thanks for taking the question.
Just two questions.
But your guidance into the availability on.
Can you comment on the availability of opportunity that's been at Trc enough portfolio that the domain.
Hi, Nick Pierre.
What see our commitment to adding some other assets.
To that point for them.
And then specifically for Cin two could you comment on.
Expectation on new product opportunity over the next few.
Few months into August 2021.
Typically if didnt give any additional color on the respiratory products.
Then also expectation for when you might be to get cut back on any final approval. Thanks.
Thank you I mean, this should also CNS opportunity as we have mentioned Thats, our top priority for from the M&A perspective.
We're looking at various products companies and.
Hey, what they were friends with our neurology fuel cells and as you know the rightfully lead product, we will add on to the movement disorder or particularly to the capex.
Category. So we remain active on that front, we are also building or getting pipeline and movement disorder, overall, which would complement it with other neurological disorders.
We went into seven is a is an example, and we are looking.
To see if we can build out external partnership.
More product partnerships.
I'll turn it over to change before the new product launches.
Yes, hi, good morning, So we there were.
We have spoken equally already be worse, the portfolio and the.
You know already.
We are confident about launching the remaining seven products in the nine to 12 months over complex Broadridge and those are mailing alone audience on Asia, we have good launches coming up in oneq or because the.
On the remote.
As far as the gloating here.
We expect.
We are cautiously optimistic that there will be a second half of 221 launch.
And regarding the respiratory products. The decline we are not giving any more color than what we had been before but it also seems like towards the end of our 21 launch, but we both get go you will be able to go to work more because.
Thank you.
The next question comes from Randall Stanicky of RBC capital markets. Please go ahead.
Great. Thanks for taking my question.
Two questions first the implied fourth quarter EBITDA based on guidance is that a good run rate for next year I think consensus supplies step up. So if you could just help us understand what some of the moving parts there.
Should that are that would be helpful. And then secondly, shrug on the topic of complex products I wanted to ask you maybe a bigger picture question here the trend landscape continues to evolve.
And obviously there is a lead time in terms of built in the pipeline at least one of your peers, who also has the branded business has called out digital therapeutics an opportunity.
Specifically, adding technology to traditional Travis.
As Emil looked at that and are there other five or five b two opportunities more.
More ways to differentiate that.
That you see that you could.
Pursue to to build out your pipeline as we think of that three to five years. Thanks.
And thank you Randall our.
We'll get back to your first question.
Later on I'll pass that on to Tussaud's, but let me go on your complex products and building out the portfolio excellent question.
As we have mentioned before we ever see any understand the really strong generics R&D.
Complex products more diverse.
Base off.
Currently categories. So we're well set on generics and we will be refreshing your pipeline every year.
Now how do we grow and Neal we have.
Additionally, then then generics so.
One focus as Biosimilars, which I mentioned it is.
It wouldn't be competitive it will be slow ramp up.
Therefore, we are more excited for the specialty business.
We have been.
We have two products in Florida in the directory with Capex into selling pipeline IP exclusive pipeline, we're looking at a drug delivery technologies, which can deliver.
More products and.
Btwos categories and the way to look at it as you know this priority today.
Basically taking the older molecules one that our goal of 30 years ago 20 years ago.
New technologies.
To make the two.
Delighted to have the lesser side effects as well as.
Patient convenience. So that is what we are working on and we see multiple opportunities and a lease.
It's not a new thing we are applying or.
Knowledge and experience in this field.
To build our systematic pipeline, which we can introduce products every year to our next five years six years seven years, we see tremendous growth and as we make sure. We can take that drug delivery technologies and move into more of programs and other technology based products.
So this is where we're positioned.
Position and knew and what we keep doing it.
But keep in mind, we're not taking your eyes off the generics business. It is a stable business growing business and we have multiple therapeutic areas, where we can constantly products every year over the next five years, we have seen so far.
Hope that answers your question on especially in genetics.
A record deal.
I'm, sorry, I just wanted to expand.
On their backlog in our complex that youd like big complex rehab.
That's part of the World.
Paul can you any however in how that will look backlog we also do.
The need for the complex either to bring to market because many products customized technologies right on a pile quite be two hour cycle at that which we talked about given quite determined using a proprietary platform to deliver that product in the third wave and vendors that are many products.
They are great molecule, but they were not that we look to properly could be worse right within the human body to give them a good efficacy and and a better profile. So we have a few technology platform on the under evaluation and the Big Bang on that and a report about those.
In order to bring that to market to provide great quality of life and better.
Our drug delivery to many me. So we are laser sharp focus on our bio probably be due by using a ready when it platforms and get ourselves going.
So a random person cover a couple a couple thousand so we.
Look at the EBITDA in Q3, we delivered $109 million.
When you look at the implied full year guidance of what this means for Q4 that imply somewhere between 96 and a 100 in the led so essentially Q4 is isn't that balka ballpark of Q3, and Q4 is a strange quarter for everybody right. So we're in the middle.
Alexia on you guys Colby you had called Cielo inventories from the holidays and so on so typically Q4, just creates just more volatility sort of ability to perfectly project Q4 for every company just it sounds both feel good about how how we'll think about Q4.
As it regards to next year.
We'll give you a guidance at the end of February. So we'll give you guys. A nano February at this point in time with US. So we're focused on is sustainability and growth. That's what we're focused on so we're not looking to be one quarter here only so anything else as a management team or looking for sustainability and growth and.
This is how we plan to oppose next year, Okay, and I think when you look at the specialty area I think we feel very good about the sustainability and the visibility of that of that business. Hopefully we'll have some additional growth as Colin subsides next year on the generic side.
You know to raise price deterioration. This year, we benefited of valuing Intercropping next year, we're likely to have some competitors that project, but there is a new pipeline the strength of the pipeline. So our expectation and our hope is that the new products right, we'll be offsetting competition on there.
On on the rest of the portfolio and finally, a c. Wright said.
We were very focused on ensuring every investor dollars gets invested properly right. So whether that is the gross to net deductions or whether or not is where we spend R&D and those DNA expenses and this year has been a good guy for us. So we're really focused on investing.
Every dollar and continue to be as efficient as we can so hopefully that gives you.
Sure enough, we think about next year.
Yeah, Hey, Tussles can I, just follow up and ask you because I just don't want this to be a.
A question lingering on the.
With respect to the stock today I mean, if you annualize Q4, youre getting $400 million EBITDA.
Consensus is close to 500 million. So do you guys have the pipeline.
Offense that that we can see.
Decent step up as we think about 2021, I know you're not going to be specific in guidance right now, but just give us some sense of.
Gee are you confident that the pipeline can support a big step up.
Yes.
My view is we cannot comment not only we or anybody else on on external consensus numbers right. So.
So so number one is when you look at this year right into the first year of those call. It turned around when the new management team, which you rockets into came in August there was a substantial step up in EBITDA right from $355 million last year too.
Two above the midpoint of the range of about 445, right. So that was a 25% increase.
Increase.
So we have seen a meaningful step up in the business.
And and everything I think we have here is how we are operating this year how were thinking about the year that focuses on sustainable growth next year and beyond.
I think thats another second as much as I can tell you at this point in time and by raising this year with a raising guidance type of EBITDA guidance.
This quarter I'm not sure that implies.
Implies things are getting worse, I think music license or getting that I'll start I'll stop there.
Okay. Thanks, guys.
The next question comes from Dana Flanders Guggenheim. Please go ahead.
Great. Thank you.
The questions.
My first one is just on the base generics business I think in your prepared remarks, you had mentioned.
Capacity utilization is back close to pre corporate levels and I know you've had a lot of success winning contracts this year.
As we look towards 2021 is that part of the list for the generics business passes now or how much of a tailwind.
Could additional.
Kind of contract wins and base business maximization be for you heading into next year and then just my second quick question on T.C. I know you had a store brand launch for V gel.
The partner about a month ago, just curious if that's a channel you plan to get bigger in and if there is a strategy around that thank you.
Thank you Dave good morning.
Our main business, we have a large commercial.
Portfolio, we have 250 products and will continue to find opportunities.
We have one of the best customer service focused just in the United States. So all three large customers and many small customers the way deep customer relationship and they're relying on our alternate supply.
[music].
Infrastructure, with U.S., and India and island coming soon.
So that allows us to keep working with our customers to add on will keep finding new opportunities within 250 products. So base business is stable and we expect to grow not counting the competition on how busy the new product launches like alluding answer probably back that.
As expected.
So we're very wary.
Proud of what we have done on the base business and rightfully. So it's a large portfolio over the years rebuild it we have been the capabilities capacity quality to supply and Thats exactly what we are doing we are one of the most reliable supplier for them and high quality and great.
Customer support and we are getting rewarded for that.
On ODC Weve been.
We have multiple or PC based is the MD eightys, which gets.
The Rx to OTC switches more than 10 products over the years, we never fully concentrated launching or DC by ourselves we've been supplying through a partner.
Sandy which happens to be re launch.
ODC distributor in the United States I believe the second largest after Banco Broward County long term relationships. We now have over 10 years with them long Island based excellent management team and boundaries. So we're expanding our reach out as we have a substantial market share already.
We were the first order introduced generics detail. So we will obviously will have a higher percentage is in that market share quarter for LTC market as well and we're looking at multiple switches from Rx to be seen we believe as it will be.
Would be more inclined to do that because of the.
The patient convenience as well as cost.
We're excited about that.
We'll look into other opportunities as well they only seem to say, it's a greenfield and we have a great partner, So we'll keep expanding our portfolio analytics.
The next question comes from Nathan Rich of Goldman Sachs. Please go ahead.
Good morning, Thanks for the question.
So far I just wanted to follow up on the topic and bio similars.
And now it's early but I'd be curious to kind of get your kind of high level view on what your commercial strategy will be in these markets.
Obviously, we're seeing kind of more options out there more competition. How are you guys thinking about pricing and kind of building market share as these approvals come.
Ladies and excellent question, we're really utilizing your specialty infrastructure led by Joe to do so.
Looking at various alternatives we have the.
Existing relationships with large wholesalers, who happen to be upholstery products. We're launching is in oncology. So they happen to be leaders CPCN Mckesson in oncology and we enjoy our years of great relationship. We wanted to finding a practical solutions. We don't believe you need.
The field sellers of hundreds of people to sell the same approved branded product again that is waste of resources and doctors get comfortable adding one more everyday is customer support physician education about biosimilars and that is where Jewish focusing more some.
Water for creative part.
Partnership with a large large.
Large already on the larger players such as Mckesson order a b C will be also in.
In play are we do want to start laying out the groundwork for what should be the biosimilars distribution why does it have to follow the traditional MRO are rewarded with a man.
Managed care partners, the Pbms and.
And that's all on the table.
I will stick with what I have said before biosimilars will become more competitive while it has a lot of products. As you know, there's 200 plus billion dollars of biologics, which are branded and that is the best way to to provide access and affordability index.
Now for the next 10 years since excellent business opportunity, but is more pricing with it the genetic sled was pretty certain players who are focused on the affordable providing affordable medicines and thats exactly the mindset, we are using to launch.
Parcel us hope.
I hope that answers your question.
Yes thats helpful. Thank you if I could just ask a very quick follow up on the tassels on the generics business.
I think earlier in the prepared remarks.
It sounds like volumes are maybe still a little bit below normal levels due to covered so I guess.
Being would you can you can you just expect to see that those volumes improve kind of as things normalize into the fourth quarter, just as we think about.
Sort of a steady state for the generic segments before considering new launches that might add to that thank you.
Yes, really really hard to answer that right. So from our perspective, we see it.
As I mentioned before in Q4 look somewhat like Q3 right.
You get half the country more than half the country exploding on call it right.
Now, we'll be done pretty well in the last nine months drives done pretty well over the last nine months.
We have I think there's some puts and takes right. So you have for example annually that should do better now and collect capacity advantage, so that should be doing better.
[music].
And and but then we have other product sometimes see some of our injectable products.
Maybe under.
Under pressure as people kind of stay out of the hospitals. So you get some puts and takes but we don't expect dramatic shift one way or the other versus say that thats, how thats, how I think about this nathan.
Yes next year.
We have said that read from now to August of next year, the eight more high value products. The seven we already launched later in his life.
Being launched soon it's approved.
Idling patch. So you can just pay them off that that complex products in high value products.
At tremendous values and this is in generics business benighted since 2002.
Every year, we must have pressure pipeline coming in commercial products, new product launches and it's exactly what any less and we have rebuilt this pipeline.
Hi, good onboard products and very excited and feel very comfortable that year over year.
Over five years, we have new product launches, which can offset compensation, which is always expected in genetics for that what do you launch the previous year.
As well as stabilizing the base business and keep finding opportunities since we have a very large base business and its keep growing.
So that I hope that answers your question.
Yes, thanks very much.
Let's see we're coming to the bottom of the hour and the last question comes from Biology Prescott of Barclays. Please go ahead.
Hi, Thanks for Clayton Man.
Morning.
And Paul slightly so its Kevin Weve been asked already so two questions from me firstly on the Biosimilars.
We just wrapped up our Genrich Andina battening Bozian bad lot of experts had the opinion might want of course that opinion that there is a strong plus more advantageously biosimilar. So tend to bring your positioning in on your last call.
Our third Raskin neupogen, and you'll be number five number sake I want to echo brains and how you think you'll be able to break this down for smaller barrier and that might pose no as I appeal secondly, I wanted to get your thoughts on Injectables as to where you are.
Currently in terms of your.
In terms of your product out on your outlook on the injectable tied for next year. Thank you.
Thank you biology good.
Good morning.
Absolutely right. The first one would would have advantage in biosimilars and it will stay there for a longer time.
As market opens up the second third fourth we'll have.
Respective market share it is difficult being pressured sales refining, creating new channels and Thats. What we are we are trying to do Goldman channels. The also the channels. The captive channels, we do not expect to match the first mover definite.
Okay.
And our future plans for Biosimilars will be more focusing on can we be forced into cost rail or second grade.
Leaving biosimilars will be very difficult to peer incurred in fourth grade. So that's exactly where we are focusing on on injectable today, we were approximately $350 million of red cells.
For full year is growing our pipeline is growing.
Focusing on.
Products, which are more again complex in nature using bad news audio.
R&D capabilities more suspension based products difficult products required trials.
Then again, bringing the first to market injectable products.
Then two completed volume.
We're also looking at various other strategies injectable very excited to grow that business over five years.
Thanks, Chad.
Thank you got it.
This concludes our question and answer session and todays annual third quarter 2020 earnings call. Thank you for attending today's presentation. You may now disconnect.
Yes.
[music].
Mm Hmm.
[noise] [noise].
[music].
Okay.
Yes.
[noise].